Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up

Article Abstract:

HIV-1 Immunogen tested in HIV-positive patients appears to induce an immune response and does not appear to cause serious side effects. HIV Immunogen is a preparation of inactivated HIV-1 that has had its gp120 protein removed from it. Researchers inoculated 25 HIV-infected volunteers, most of whom had some symptoms related to HIV infection, with HIV-1 Immunogen an average of 8 times over 3 years. Volunteers were followed for laboratory assessment for an average of 3.8 years after starting the study, and were followed for clinical assessment for an average of 5.8 years. No serious side effects were seen. An accelerated course of HIV disease was also not observed. Twelve volunteers exhibited strong delayed-type hypersensitivity (DTH) to the HIV-1 Immunogen applied to their skin, indicating the presence of an immune response resulting from the drug. Two of these 12 volunteers developed AIDS, and one of the two died. Nine of the 13 volunteers with weak DTH responses developed AIDS, and 7 died. Laboratory results were also more promising in the group with a strong DTH response.

Measurement, HIV infection, Drug therapy, HIV infections, Immunotherapy, Delayed hypersensitivity

---

Treatment of adult T-cell leukemia-lymphoma with combination of interferon alfa and zidovudine

Article Abstract:

Interferon alfa combined with zidovudine may be effective in treating adult T-cell leukemia-lymphoma. This type of cancer is caused by a viral infection and has a poor prognosis. Researchers treated 19 patients with the disease with 200 mg of zidovudine 5 times per day and 5 million units of interferon alfa. A remission of all malignancies for at least 4 weeks was classified as a complete response; a 50% decrease in quantitative indicators of the disease was classified as a partial response. Of the 19 patients, 5 had a complete response and 6 had a partial response. Of 7 patients who did not respond to other treatments, 4 responded to this therapy. The median survival of the 11 patients who responded to therapy was 13 months. Side effects from the drugs included a drop in white blood cells and platelets, fever, fatigue, nausea, and vomiting.

Chemotherapy, Zidovudine, Interferon alpha, Adult T-cell leukemia-lymphoma

---

Similar abstracts:

• Abstracts: Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. part 2 Human immunodeficiency virus infection in tuberculosis patients
• Abstracts: Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. NIH conference: development and evaluation of a vaccine for human immunodeficiency virus (HIV) infection
• Abstracts: Zidovudine (AZT) for treatment of patients infected with human immunodeficiency virus type I: an evaluation of effectiveness in clinical practice
• Abstracts: High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advanced HIV infection

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.